Drug interactions
Larotrectinib + Upadacitinib
Severity: Minor
Larotrectinib and Upadacitinib: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Larotrectinib is a substrate of CYP3A4 and a weak inhibitor of it in vitro, so a small increase in upadacitinib exposure is possible. Clinical significance is unestablished and likely minimal.
What this interaction means in plain words
Larotrectinib and Upadacitinib have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Larotrectinib belongs to Oncology; Upadacitinib belongs to Musculoskeletal.
Why it happens
Possible weak CYP3A4 inhibition by larotrectinib; the mechanism is not firmly established.
What to do
No routine adjustment is needed; monitor for upadacitinib adverse effects such as infection and cytopenias.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Larotrectinib and Upadacitinib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Upadacitinib
- Abrocitinib + Upadacitinib Contraindicated
- Adenovirus types 4 and 7 live + Upadacitinib Contraindicated
- Baricitinib + Upadacitinib Contraindicated
- Bcg vaccine live + Upadacitinib Contraindicated
- Cyclosporine + Upadacitinib Contraindicated
- Dengue vaccine + Upadacitinib Contraindicated
Other interactions of Larotrectinib
Frequently asked questions
Can I take Larotrectinib with Upadacitinib?
MediHelp rates the interaction as minor. Larotrectinib and Upadacitinib have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Larotrectinib is a substrate of CYP3A4 and a weak inhibitor of it in vitro, so a small increase in upadacitinib exposure is possible. Clinical significance is unestablished and likely minimal.
How serious is the interaction between Larotrectinib and Upadacitinib?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: No routine adjustment is needed; monitor for upadacitinib adverse effects such as infection and cytopenias.
What other medicines interact with Upadacitinib?
MediHelp also lists interactions of Upadacitinib with, for example, Abrocitinib, Adenovirus types 4 and 7 live, Baricitinib. The full list is on the Upadacitinib page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
